Search

Your search keyword '"Cleton-Jansen, Anne-Marie"' showing total 631 results

Search Constraints

Start Over You searched for: Author "Cleton-Jansen, Anne-Marie" Remove constraint Author: "Cleton-Jansen, Anne-Marie"
631 results on '"Cleton-Jansen, Anne-Marie"'

Search Results

1. Formalin-Fixed, Paraffin-Embedded–Targeted Locus Capture: A Next-Generation Sequencing Technology for Accurate DNA-Based Gene Fusion Detection in Bone and Soft Tissue Tumors

4. Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

8. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing

9. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation

16. Supplementary Data from Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors

17. Supplementary material from Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression

18. Supplementary Data from Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

19. Supplementary Figure 2 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

20. Supplementary Figure 1 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

21. Supplementary Figure 1 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer

22. Supplementary Methods, Figure Legends 1-3, Table Legends 1-6 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

23. Supplementary Table 1 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer

24. Supplementary Tables 1-6 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

25. Supplementary Table 2 from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer

26. Data from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

27. Supplementary Methods and Materials from Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer

28. Supplementary Figure 3 from Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

29. No NFATC2 fusion in simple bone cyst of the jaw

30. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia

34. SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin

36. Expanding the Spectrum of EWSR1-NFATC2-rearranged Benign Tumors

38. Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma

40. Additional file 1 of Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

41. Additional file 2 of Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial)

47. List of Contributors

49. NTRK fusions are extremely rare in bone tumours

Catalog

Books, media, physical & digital resources